Tolerability of Alternative Dosing Schedules for Sunitinib: A Systematic Review and Meta-Analysis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The standard schedule for sunitinib treatment is 4 weeks on and 2 weeks off (4/2) in first-line treatment for metastatic renal cell carcinoma (mRCC). Schedule modifications, including 2 weeks on and 1 week off (2/1), appear to reduce the total number of treatment-related adverse events (TRAEs) without compromising efficacy. Even though TRAEs can qualitatively differ fromeach other, it is not clear as to what effects a 2/1 schedule has on individual TRAEs. Materials and Methods: This meta-analysis included one randomized controlled trial (RCT) and four non-randomized controlled studies (non-RCTs) that compared the two schedules in parallel. The primary objective was to estimate risk of individual adverse events (AEs) with a sunitinib 2/1 schedule versus a 4/2 schedule. Seven representative AEs were evaluated as standard data for the RCT and as weighted pooling data of the non-RCTs. Random effects modelling with Review Manager v5.3 was used to pool study-level data using the inverse-variance of each study as the weight. Results: The five selected studies included a total of 484 patients with mRCC. Risk ratios for fatigue for a 2/1 schedule were significantly lower than those for a 4/2 schedule {0.69 [95% confidence intervals (CI), 0.51, 0.95] in the RCT and 0.77 (95% CI, 0.63, 0.94) in the non-RCTs}. Other TRAEs, except diarrhea and anorexia, also tended to decrease in both sets. Efficacy outcomes were comparable between 2/1 and standard schedules. Conclusion: This meta-analysis suggests that a 2/1 schedule of sunitinib lowers the risk of fatigue and the occurrence other AEs without compromising efficacy.
Abstract
Purpose: The standard schedule for sunitinib treatment is 4 weeks on and 2 weeks off (4/2) in first-line treatment for metastatic renal cell carcinoma (mRCC). Schedule modifications, including 2 weeks on and 1 week off (2/1), appear to reduce the total number of treatment-related adverse events (TRAEs) without compromising efficacy. Even though TRAEs can qualitatively differ fromeach other, it is not clear as to what effects a 2/1 schedule has on individual TRAEs. Materials and Methods: This meta-analysis included one randomized controlled trial (RCT) and four non-randomized controlled studies (non-RCTs) that compared the two schedules in parallel. The primary objective was to estimate risk of individual adverse events (AEs) with a sunitinib 2/1 schedule versus a 4/2 schedule. Seven representative AEs were evaluated as standard data for the RCT and as weighted pooling data of the non-RCTs. Random effects modelling with Review Manager v5.3 was used to pool study-level data using the inverse-variance of each study as the weight. Results: The five selected studies included a total of 484 patients with mRCC. Risk ratios for fatigue for a 2/1 schedule were significantly lower than those for a 4/2 schedule {0.69 [95% confidence intervals (CI), 0.51, 0.95] in the RCT and 0.77 (95% CI, 0.63, 0.94) in the non-RCTs}. Other TRAEs, except diarrhea and anorexia, also tended to decrease in both sets. Efficacy outcomes were comparable between 2/1 and standard schedules. Conclusion: This meta-analysis suggests that a 2/1 schedule of sunitinib lowers the risk of fatigue and the occurrence other AEs without compromising efficacy.
참고문헌 (24)
- Escudier B, "Renal cell carcinoma : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 30, pp.706~720 (2019)
- Houk BE, "Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer : results of a pharmacokinetic", pharmacodynamic meta-analysis, 2010, pp.66, 357~371
- Patil S, "Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α", Br J Cancer, 106, pp.1587~1590 (2012)
- Motzer RJ, "Sunitinib versus interferon alfa in metastatic renal-cell carcinoma", N Engl J Med, 356, pp.115~124 (2007)
- Fiedler W, "A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia(AML)or not amenable to conventional therapy for the disease", Blood, 105, pp.986~993 (2005)
- Faivre S, "Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer", J Clin Oncol, 24, pp.25~35 (2006)
- Motzer RJ, "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma", J Clin Oncol, 24, pp.16~24 (2006)
- Faivre S, "Molecular basis for sunitinib efficacy and future clinical development", Nat Rev Drug Discov, 6, pp.734~745 (2007)
- Neri B, "The efficacy and tolerability of a sunitinib 3-week administration schedule in metastatic renal cell carcinoma patients : report of three cases", Oncol Res, 20, pp.259~264 (2012)
- Atkinson BJ, "Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules", J Urol, 191, pp.611~618 (2014)
- Bjarnason GA, "Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy : correlation with dynamic microbubble ultrasound data and review of the literature", Urol Oncol, 32, pp.480~487 (2014)
- Lee JL, "RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma : RESTORE trial", Ann Oncol, 26, pp.2300~2305 (2015)
- Moher D, "Preferred reporting items for systematic reviews and meta-analyses : the PRISMA statement", Ann Intern Med, 151, pp.264~269 (2009)
- Pan X, "Sunitinib dosing schedule 2", 1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma, 2015, pp.33, 268e9~268e15
- Bracarda S, "Sunitinib administered on 2", 1 schedule in patients with metastatic renal cell carcinoma : the RAINBOW analysis, 2015, pp.26, 2107~2113
- Kondo T, "Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weekson and 2-weeks-off", Jpn J Clin Oncol, 44, pp.270~277 (2014)
- Neri B, "Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma : a single-center experience with 31 patients", Int J Urol, 20, pp.478~483 (2013)
- Britten CD, "A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period", Cancer Chemother Pharmacol, 61, pp.515~524 (2008)
- Miyake H, "Improved healthrelated quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib", Med Oncol, 32, pp.78~ (2015)
- Schmidinger M, "Understanding and managing toxicities of vascular endothelial growth factor(VEGF)inhibitors", EJC Suppl, 11, pp.172~191 (2013)
- Santoni M, "Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors : an up-to-date review and meta-analysis of clinical trials", Int J Cancer, 136, pp.1~10 (2015)
- Najjar YG, "A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma", Eur J Cancer, 50, pp.1084~1089 (2014)
- Walko CM, "Pharmacoepidemiology of clinically relevant hypothyroidism and hypertension from sunitinib and sorafenib", Oncologist, 22, pp.208~212 (2017)
- Yuan A, "Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors", Oral Oncol, 51, pp.1026~1033 (2015)